Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 77,853 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 77,853 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $50.09, for a total transaction of $3,899,656.77. Following the transaction, the chief executive officer now directly owns 2,069,456 shares in the company, valued at $103,659,051.04. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The shares were sold at an average price of $50.07, for a total transaction of $1,990,332.57.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The shares were sold at an average price of $50.00, for a total transaction of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84.

Guardant Health Trading Up 3.1%

Shares of NASDAQ GH traded up $1.47 during midday trading on Monday, hitting $49.53. The company’s stock had a trading volume of 2,926,769 shares, compared to its average volume of 2,130,739. The stock has a fifty day moving average price of $43.05 and a 200 day moving average price of $41.25. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.91 and a beta of 1.37.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. On average, equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. TD Securities raised their price target on shares of Guardant Health from $56.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Barclays lifted their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, May 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 price objective (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Finally, Stephens reaffirmed an “overweight” rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $53.29.

Hedge Funds Weigh In On Guardant Health

Hedge funds have recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in Guardant Health during the first quarter valued at approximately $54,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman & Baird LLC purchased a new position in Guardant Health during the fourth quarter valued at approximately $58,000. NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after acquiring an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health during the fourth quarter valued at approximately $61,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.